Lisata Therapeutics (NASDAQ:LSTA) reported quarterly losses of $(7.88) per share. This is a 352.87 percent decrease over losses of $(1.74) per share from the same period last year.
Roth Capital Downgrades Ayala Pharmaceuticals to Sell, Lowers Price Target to $0.55
Roth Capital analyst Tony Butler downgrades Ayala Pharmaceuticals (NASDAQ:AYLA) from Buy to Sell and lowers the price target from $14 to $0.55.